CD73在三阴性乳腺癌中的临床意义:III期临床试验多重分析
该研究基于BIG 02-98 III期临床试验中122例三阴性乳腺癌样本,用多重免疫荧光分析CD73在肿瘤细胞、浸润白细胞和基质细胞上的表达。结果发现上皮肿瘤细胞高表达CD73与无病生存和总生存降低显著相关,且与肿瘤免疫浸润负相关。CD73高表达且肿瘤浸润白细胞低的患者临床结局最差。
要点
- 上皮肿瘤细胞高CD73表达与TNBC患者DFS和OS降低显著相关。
- CD73表达与肿瘤免疫浸润呈负相关(Spearman R=-0.50,P<0.0001)。
- CD73高表达且浸润白细胞低的TNBC患者临床结局最差。
核心结论
- CD73表达与三阴性乳腺癌不良预后和抗肿瘤免疫减弱相关,靶向CD73可能是重编程该亚型肿瘤微环境的策略。
研究设计与样本
- 基于BIG 02-98辅助III期临床试验的122例三阴性乳腺癌福尔马林固定石蜡包埋原发肿瘤样本,采用多重免疫荧光和图像分析评估CD73蛋白表达。
主要发现
- 上皮肿瘤细胞高CD73表达与无病生存和总生存降低显著相关。
- CD73表达与肿瘤免疫浸润负相关(Spearman R=-0.50,P<0.0001)。
- CD73高表达且肿瘤浸润白细胞低的患者临床结局最差。
关键数值与推荐
- CD73表达与肿瘤免疫浸润的Spearman相关系数R=-0.50,P<0.0001。
临床怎么用
- CD73高表达且免疫浸润低的三阴性乳腺癌患者预后更差,检测CD73与免疫浸润可能有助于风险分层。
- 靶向CD73或腺苷受体通路可能成为三阴性乳腺癌的治疗策略。
局限性
- 样本来自单一III期临床试验的122例三阴性乳腺癌,结论需更大队列验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: CD73 is an ecto-enzyme that promotes tumor immune escape through the production of immunosuppressive extracellular adenosine in the tumor microenvironment. Several CD73 inhibitors and adenosine receptor antagonists are being evaluated in phase I clinical trials. PATIENTS AND METHODS: Full-face sections from formalin-fixed paraffin-embedded primary breast tumors from 122 samples of triple-negative breast cancer (TNBC) from the BIG 02-98 adjuvant phase III clinical trial were included in our analysis. Using multiplex immunofluorescence and image analysis, we assessed CD73 protein expression on tumor cells, tumor-infiltrating leukocytes and stromal cells. We investigated the associations between CD73 protein expression with disease-free survival (DFS), overall survival (OS) and the extent of tumor immune infiltration. RESULTS: Our results demonstrated that high levels of CD73 expression on epithelial tumor cells were significantly associated with reduced DFS, OS and negatively correlated with tumor immune infiltration (Spearman's R= -0.50, P < 0.0001). Patients with high levels of CD73 and low levels of tumor-infiltrating leukocytes had the worse clinical outcome. CONCLUSIONS: Taken together, our study provides further support that CD73 expression is associated with a poor prognosis and reduced anti-tumor immunity in human TNBC and that targeting CD73 could be a promising strategy to reprogram the tumor microenvironment in this BC subtype.
引用
- Buisseret L, Pommey S, Allard B, et al. Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial. Ann Oncol. 2018. PMID: 29145561. doi:10.1093/annonc/mdx730
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。